Opioid-Refractory Pain Management Support Protocol
Primary Stack
Core supplements with strongest evidenceEndocannabinoid-like compound; anti-inflammatory; analgesic through multiple mechanisms
Supporting Studies (1)
Antioxidant; effective for neuropathic pain; reduces nerve damage
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsNMDA receptor modulator; may reduce central sensitization; helps with muscle pain
Supporting Studies (1)
Anti-inflammatory; modulates multiple pain pathways; well-tolerated
Supporting Studies (1)
Anti-inflammatory; reduces pro-inflammatory mediators; supports nerve health
Supporting Studies (1)
Deficiency common in chronic pain; correction may reduce pain levels
Supporting Studies (1)
Anti-inflammatory; inhibits 5-lipoxygenase; may help with various pain conditions
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Opioid-refractory pain refers to chronic pain that does not respond adequately to opioid medications, or where opioids cannot be used due to side effects, risks, or other factors. This is increasingly recognized as a distinct management challenge.
WHY PAIN MAY NOT RESPOND TO OPIOIDS:
TYPES OF PAIN LESS RESPONSIVE TO OPIOIDS:
MULTIMODAL APPROACH IS KEY:
Non-Opioid Medications:
Interventional Options:
Non-Pharmacological:
* PEA is a well-studied alternative with good evidence for chronic pain.
* Alpha-lipoic acid is particularly helpful for neuropathic pain.
* Magnesium may help reduce central sensitization.
Expected timeline: Multimodal approaches require weeks to months to optimize. Supplements may provide additional modest benefit.
Clinical Perspective
Opioid-Refractory Pain: Chronic pain inadequately controlled by or unsuitable for opioid therapy. Causes include neuropathic pain mechanisms, central sensitization, opioid-induced hyperalgesia, tolerance, inadequate dosing for cancer pain, or contraindications to opioids. Prevalence: 30-40% of chronic pain patients.
CRITICAL: Multimodal approach essential. Non-opioid medications (SNRIs, TCAs, gabapentinoids) may be more effective for neuropathic pain. Interventional procedures for appropriate candidates. Psychological treatments address central sensitization and suffering. Physical therapy for function. Ketamine for select cases. PEA and ALA have reasonable evidence. Supplements are adjunctive - part of multimodal strategy, not sole treatment.
* PEA (B-grade): Endocannabinoid-like. Meta-analysis: (PMID: 27015276). 600-1200mg daily. Good safety profile.
* Alpha-Lipoic Acid (B-grade): Neuropathic pain. Meta-analysis: (PMID: 26376825). 600-1200mg daily.
* Magnesium (C-grade): NMDA modulation. Systematic review: (PMID: 28445426). 400-600mg daily.
* Curcumin (C-grade): Anti-inflammatory. Systematic review: (PMID: 25282711). 500-1500mg daily (enhanced absorption).
* Omega-3 (C-grade): Anti-inflammatory. Review: (PMID: 27840029). 2-4g EPA+DHA daily.
* Vitamin D (C-grade): Common deficiency. Meta-analysis: (PMID: 28750270). 2000-4000 IU daily.
* Boswellia (C-grade): 5-LOX inhibition. Systematic review: (PMID: 22426836). 300-500mg TID.
Assessment targets: Pain scales (NRS, BPI), function, sleep, mood, medication use, quality of life.
Protocol notes: Pain phenotyping: identify predominant mechanisms (nociceptive, neuropathic, nociplastic). SNRIs: duloxetine, venlafaxine - evidence for neuropathic, fibromyalgia, chronic musculoskeletal. Gabapentinoids: gabapentin, pregabalin - neuropathic pain, fibromyalgia. TCAs: amitriptyline, nortriptyline - neuropathic pain, headache. Ketamine: IV or intranasal for refractory pain; requires monitoring. SCS: spinal cord stimulation for CRPS, FBSS, neuropathic pain. Psychology: CBT for pain, ACT, mindfulness - address catastrophizing, fear-avoidance. Physical therapy: graduated exercise, pacing, desensitization. Opioid-induced hyperalgesia: suspect if increasing doses worsen pain; may need rotation or reduction. Methadone: NMDA antagonist properties; useful for neuropathic pain; QTc monitoring needed. Cannabis/CBD: some patients report benefit; limited quality evidence; legal issues.